Diagnostic and therapeutic challenges in a liver transplant recipient with central nervous system invasive aspergillosis

Diagnostic Microbiology and Infectious Disease

Volumn 73, Issue 4, 2012, Pages 374-375

  Neofytos, Dionissios ^a   Shoham, Shmuel ^a   Dierberg, Kerry ^a   Le, Katharine ^a   Dufresne, Simon ^a   Zhang, Sean X ^a   Marr, Kieren A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Central nervous system infection; Invasive aspergillosis; Liver transplant recipient

Indexed keywords

COTRIMOXAZOLE; FLUCONAZOLE; GANCICLOVIR; METHYLPREDNISOLONE; MICAFUNGIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; VORICONAZOLE;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; BRAIN BIOPSY; BRAIN HEMORRHAGE; BRONCHOSCOPY; CASE REPORT; CENTRAL NERVOUS SYSTEM ASPERGILLOSIS; CEREBROSPINAL FLUID ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DRUG MEGADOSE; DRUG WITHDRAWAL; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE COUNT; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LUNG HEMORRHAGE; LYMPHOCYTE COUNT; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL DENSITY; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; TONIC CLONIC SEIZURE;

ADOLESCENT; ANTIFUNGAL AGENTS; HUMANS; IMMUNOCOMPROMISED HOST; LIVER TRANSPLANTATION; MALE; MICROBIOLOGICAL TECHNIQUES; MYCOLOGY; NEUROASPERGILLOSIS; TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84863774640     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.05.001     Document Type: Article

References (20)

1. Bonham C.A., Dominguez E.S., Fukui M.F., Paterson D.L., Pankey G.A., Wagener M.M., et al. Central nervous system lesions in liver transplant recipients: prospective assessment of indications for biopsy and implications for management. Transplantation 1998, 66:1596-1604.
2. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821. European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group, National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupNational Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.
3. Denning D.W. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996, 23:608-615.
4. Garcia-Vidal C., Upton A., Kirby K., Marr K.A. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008, 47:1041-1050.
5. Johnson H.J., Han K., Capitano B., Blisard D., Husain S., Linden P.K., et al. Voriconazole pharmacokinetics in liver transplant recipients. Antimicrob Agents Chemother 2010, 54:852-859.
6. Klont R.R., Mennink-Kersten M.A., Verweil P.E. Utility of Aspergillus antigen detection in specimens other than serum specimens. Clin Infect Dis 2004, 39:1467-1474.
7. Lin S.J., Schranz J., Teutsch S.M. Aspergillosis case fatality rate: Systematic Review of the Literature. Clin Infect Dis 2001, 32:358-365.
8. Lutsar I., Roffey S., Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003, 37:728-732.
9. Machetti M., Zotti M., Veroni L., Mordini N., Van Lint M.T., Bacigalupo A., et al. Antigen detection in the diagnosis and management of a patient with probable cerebral aspergillosis treated with voriconazole. Transpl Infect Dis 2002, 3:140-144.
10. Marr K.A., Boeckh M., Carter R.A., Kim H.W., Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004, 39:797-802.
11. Neofytos D., Horn D., Anaissie E., Steinbach W., Olyaei A., Fishman J., et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009, 48:265-273.
12. Neofytos D., Fishman J.A., Horn D., Anaissie E., Chang C.H., Olyaei A., et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010, 12:220-229.
13. Nivoix Y., Velten M., Letscher-Bru V., Moghaddam A., Natarajan-Amé S., Fohrer C., et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008, 47:1176-1184.
14. Pappas P.G., Alexander B.D., Andes D.R., Hadley S., Kauffman C.A., Freifeld A., et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010, 50:1101-1111.
15. Singh N., Limaye A.P., Forrest G., Safdar N., Muñoz P., Pursell K., et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006, 81:320-326.
16. Upton A., Kirby K.A., Carpenter P., Boeckh M., Marr K.A. Invasive aspergillosis following hematopoietic cell transplantation: Outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007, 44:531-540.
17. Verweij P., Brinkman K., Kremer H.P., Kullberg B.J., Meis J.F. Aspergillus meningitis: diagnosis by non-culture-based microbiological methods and management. J Clin Microbiol 1999, 37:1186-1189.
18. Viscoli C., Machetti M., Gazzola P., De Maria A., Paola D., Van Lint M.T., et al. Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J Clin Microbiol 2002, 40:1496-1499.
19. Walsh T.J., Karlsson M.O., Driscoll T., Arquedas A.G., Adamson P., Saez-Llorens X., et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004, 48:2166-2172.
20. Walsh T.J., Anaissie E.J., Denning D.W., Herbrecht R., Kontoyiannis D.P., Marr K.A., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:327-360.